UBS Group
CRSP icon

UBS Group’s CRISPR Therapeutics CRSP Stock Holding History

UBS Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,000
Closed -$2.59M – 10598
2025
Q3 		$2.59M Buy
+40,000
New +$2.3M ﹤0.01% 4706

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's CRSP Position: Q2 2026 in Review

UBS Group reduced its CRISPR Therapeutics (CRSP) stake by 25% in Q2 2026, selling an estimated $23.5M and leaving 1,317,499 shares worth $71.9M. The position accounts for 0.01% of the portfolio, ranked #1394.

UBS Group first reported a position in CRSP in Q4 2016 and has held it in 39 quarters since. The position peaked at $152M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • UBS Group held 1,317,499 shares of CRISPR Therapeutics worth $71.9M as of Q2 2026.
  • UBS Group sold 445,031 CRISPR Therapeutics shares in Q2 2026, an estimated $23.5M.
  • CRISPR Therapeutics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1394 holding.
  • UBS Group first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • UBS Group's CRISPR Therapeutics position peaked at $152M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.